Tukysa

Active Ingredient(s): Tucatinib
FDA Approved: * April 17, 2020
Pharm Company: * SEATTLE GENETICS
Category: Cancer

Tucatinib, sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer.[4][5] It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).[6] Common side effects are diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tukysa 50 mg Oral Tablet
NDC: 51144-001
Labeler:
Seattle Genetics, Inc.
Tukysa 150 mg Oral Tablet
NDC: 51144-002
Labeler:
Seattle Genetics, Inc.